Compare Citius Pharmaceuticals Inc (CTXR) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Gartner Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Gartner Inc trades at $191.18 (market cap $12.34B). The key difference: Gartner Inc is far larger — about 906× Citius Pharmaceuticals Inc's market cap, and Gartner Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Gartner Inc for 64 Days on average.
| CTXR | IT | |
|---|---|---|
Market Cap | $13.62M | $12.34B |
Volume | 132,438 | 919,809 |
Sector | Health | Technology |
52-Week High | $1.82 | $258.17 |
52-Week Low | $0.48 | $125.68 |
Typical Hold Time | 17 Days | 64 Days |
Enterprise Value | $3.79M | $14.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Gartner (IT) trades at $191.02, up 2.83% with a bullish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Financials show strong profitability with a 69.63% gross margin and 113.58% ROE, though net income declined in 2025. Recent news highlights AI advisory demand and Gartner's industry leadership, driving positive sentiment.
Outlook remains supported by robust contract value and AI-driven consulting growth, but risks include a high P/B ratio of 160.06 and a shareholder investigation. Analyst consensus is mixed with a $174.63 price target below the current price, suggesting caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
